Abstract

In October 1997, we reviewed ▼donepezil (Aricept-Eisai; Pfizer) as a new treatment for Alzheimer's disease and, on the evidence available, could not recommend its use. We argued that the position would change if more tangible evidence became available showing that the product offers real improvement in patients' wellbeing.1 Since then, the results of two more randomised controlled trials have been published,2^,3 as has a long-term follow-up study of participants in the original study.4^,5 Here we review our position, taking into account these new data.